Alumis said on Tuesday its experimental drug met the main goal of improving symptoms of a common skin disease in two late-stage studies, powering its shares to a record high and more than doubling ...
Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...
RAAINBOW-2 is an international, double-blind, placebo-controlled Phase 3 study for the treatment of moderate to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback